Keay Nakae
Stock Analyst at Chardan Capital
(3.47)
# 930
Out of 4,712 analysts
199
Total ratings
32.65%
Success rate
9.16%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $30 → $20 | $1.42 | +1,308.45% | 12 | Dec 20, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $2.67 | +49.81% | 13 | Dec 12, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $19.63 | +205.65% | 17 | Dec 12, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 | $7.00 | +685.71% | 10 | Dec 10, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $4.5 → $5 | $3.18 | +57.23% | 11 | Nov 20, 2024 | |
| ALUR Allurion Technologies | Downgrades: Neutral | n/a | $0.39 | - | 4 | Nov 14, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $1.25 | $0.96 | +30.21% | 8 | Nov 13, 2024 | |
| FEMY Femasys | Maintains: Buy | $10 → $8 | $1.11 | +620.72% | 10 | Nov 13, 2024 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.70 | +325.53% | 7 | Nov 13, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $23.97 | +108.59% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 | $31.35 | +107.34% | 12 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 | $5.42 | +158.54% | 14 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $4.10 | +509.77% | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 | $243.25 | +23.33% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.59 | +277.36% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.83 | +620.98% | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.42 | +107.01% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.39 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $17.02 | -64.75% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.54 | +3,578.50% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.30 | +562.65% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $17.18 | -41.79% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $19.70 | +344.16% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.72 | +1,710.08% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.16 | +1,751.85% | 2 | Jun 30, 2020 |
Sonnet BioTherapeutics Holdings
Dec 20, 2024
Maintains: Buy
Price Target: $30 → $20
Current: $1.42
Upside: +1,308.45%
ProQR Therapeutics
Dec 12, 2024
Maintains: Buy
Price Target: $4
Current: $2.67
Upside: +49.81%
Arrowhead Pharmaceuticals
Dec 12, 2024
Maintains: Buy
Price Target: $60
Current: $19.63
Upside: +205.65%
Silence Therapeutics
Dec 10, 2024
Maintains: Buy
Price Target: $55
Current: $7.00
Upside: +685.71%
Arbutus Biopharma
Nov 20, 2024
Maintains: Buy
Price Target: $4.5 → $5
Current: $3.18
Upside: +57.23%
Allurion Technologies
Nov 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Seres Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $1.25
Current: $0.96
Upside: +30.21%
Femasys
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.11
Upside: +620.72%
Orchestra BioMed Holdings
Nov 13, 2024
Maintains: Buy
Price Target: $20
Current: $4.70
Upside: +325.53%
Dyne Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $50
Current: $23.97
Upside: +108.59%
Nov 13, 2024
Maintains: Buy
Price Target: $65
Current: $31.35
Upside: +107.34%
Nov 7, 2024
Maintains: Buy
Price Target: $14
Current: $5.42
Upside: +158.54%
Nov 7, 2024
Maintains: Buy
Price Target: $25
Current: $4.10
Upside: +509.77%
Nov 1, 2024
Maintains: Buy
Price Target: $300
Current: $243.25
Upside: +23.33%
Aug 9, 2024
Maintains: Buy
Price Target: $6
Current: $1.59
Upside: +277.36%
Aug 7, 2024
Maintains: Buy
Price Target: $7 → $6
Current: $0.83
Upside: +620.98%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $2.42
Upside: +107.01%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.39
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $17.02
Upside: -64.75%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.54
Upside: +3,578.50%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.30
Upside: +562.65%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $17.18
Upside: -41.79%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $19.70
Upside: +344.16%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.72
Upside: +1,710.08%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.16
Upside: +1,751.85%